Spri Clinical Trials LLC

1. ITI, Inc. $1,056,394 76 payments
2. Sage Therapeutics, Inc. $966,491 77 payments
3. Axsome Therapeutics, Inc. $578,154 13 payments
4. Imbrium Therapeutics L.P. $454,275 20 payments
5. Janssen Research & Development, LLC $409,478 20 payments
6. Biohaven Pharmaceutical Holding Company Ltd. $374,517 11 payments
7. Otsuka Pharmaceutical Development & Commercialization, Inc. $358,345 14 payments
8. ACADIA Pharmaceuticals Inc $216,234 24 payments
9. Supernus Pharmaceuticals, Inc. $194,544 12 payments
10. Pfizer Inc. $138,814 18 payments

1. A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $578,154 13 payments
2. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $423,197 26 payments
3. An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $418,757 31 payments
4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $388,536 45 payments
5. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $336,080 13 payments
6. Oag2002 $292,964 10 payments
7. A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $291,221 9 payments
8. A Phase 4 Openlabel Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $202,604 13 payments
9. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $201,556 2 payments
10. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $194,544 12 payments

1. Patient care $132,531 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.